3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Breast Cancer Female
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
6
Radiotherapy
5
Carboplatin
5
capmatinib
2
Radiosurgery
2
Gemcitabine
2
tetrathiomolybdate
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
onartuzumab
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
efaproxiral
1
durvalumab
1
binimetinib
1
aldesleukin
1
Vinorelbine
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sorafenib
1
Platinum
1
Nivolumab
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gefitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma of Lung
×
durvalumab
×
Clear all
NCT04944173
2024-09-03
SCION
University of British Columbia
Phase 2
Withdrawn